Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT ™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK, Aug. 14,…#hepzatokit #fda #businessupdatecall #easterntime #delcathsystems #nccn #php #hepzatokitmarks #gerardmichel #nct02678572
Source: Reuters: Health - Category: Consumer Health News Source Type: news